Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: Results from a phase IIIb study (NCT00831233)

Urologia Internationalis

Volumn 90, Issue 3, 2013, Pages 321-328

  Anderson, John ^a   Al Ali, Ghandi ^b   Wirth, Manfred ^c   Gual, Joan Benejam ^d   Gomez Veiga, Francisco ^e   Colli, Enrico ^f   Van Der Meulen, Egbert ^g   Persson, Bo Eric ^g  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b Urologisches Gesundheitszentrum   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d HOSPITAL DE MANACOR   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f Ferring Pharmaceuticals   (Spain)

^g Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Degarelix; Goserelin; Lower urinary tract symptoms; Prostate cancer

Indexed keywords

BICALUTAMIDE; DEGARELIX; GOSERELIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; HOT FLUSH; HUMAN; INJECTION SITE REACTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIVER FAILURE; LOWER URINARY TRACT SYMPTOM; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SIZE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION; URINE RETENTION;

EID: 84876860862     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000345423     Document Type: Article

References (30)

1. Bright E, Abrams P: Diseases of the prostate. Rev Clin Gerontol 2010; 20: 10-19.
2. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651-658.
3. Gammack JK: Lower urinary tract symptoms. Clin Geriatr Med 2010; 26: 249-260.
4. Batista-Miranda JE, Molinuevo B, Pardo Y: Impact of lower urinary tract symptoms on quality of life using Functional Assessment Cancer Therapy scale. Urology 2007; 69: 285-288.
5. Kumar V, Toussi H, Marr C, Hough C, Javle P: The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer. BJU Int 2004; 93: 507-509.
6. Lepor H, Kaci L: The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: A prospective assessment using validated self-administered outcome instruments. J Urol 2004; 171: 1216-1219.
7. Gnanapragasam VJ, Kumar V, Langton D, Pickard RS, Leung HY: Outcome of transurethral prostatectomy for the palliative management of lower urinary tract symptoms in men with prostate cancer. Int J Urol 2006; 13: 711-715.
8. Ponholzer A, Brossner C, Struhal G, Marszalek M, Madersbacher S: Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World J Urol 2006; 24: 325-330.
9. Eckman MH, Ying J, Hertzfeld K, Kumar N, Barrett W: Longitudinal analysis of genitourinary and bowel symptoms in prostate cancer patients following brachytherapy. Am J Clin Oncol 2010; 33: 1-10.
10. Laborde EE, McVary KT: Medical management of lower urinary tract symptoms. Rev Urol 2009; 11:S19-S25.
11. Crawford ED, Kavanagh BD: The role of -blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy. Am J Clin Oncol 2006; 29: 517-523.
12. Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B: Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 361-379.
13. Van Poppel H, Nilsson S: Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008; 71: 1001-1006.
14. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schroder FH: The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-1538.
15. Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold OT, Persson BE: Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010; 57: 836-842.
16. Barry MJ, O'Leary MP: Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am 1995; 22: 299-307.
17. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK: A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 1986-1992.
18. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT: Degarelix: A novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-year, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008; 54: 805-813.
19. Langenhuijsen JF, van Lin EN, Hoffmann AL, Spitters-Post I, Alfred WJ, Kaanders JH, Mulders PF: Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol 2011; 29: 52-57.
20. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B: Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology 2006; 68: 116-120.
21. Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C: Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 2007; 320: 1113-1118.
22. Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de MR, Millar RP: Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004; 64: 7533-7544.
23. Tang X, Yano T, Osuga Y, Matsumi H, Yano N, Xu J, Wada O, Koga K, Kugu K, Tsutsumi O, Schally AV, Taketani Y: Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J Clin Endocrinol Metab 2002; 87: 3721-3727.
24. Lamharzi N, Halmos G, Jungwirth A, Schally AV: Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 1998; 13: 429-435.
25. Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L: LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71: 736-747.
26. Porter AT, Ben-Josef E: Humoral mechanisms in prostate cancer: A role for FSH. Urol Oncol 2001; 6: 131-138.
27. Garde SV, Sheth AR, Shah MG, Kulkarni SA: Prostate-an extrapituitary source of follicle-stimulating hormone: occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents. Prostate 1991; 18: 271-287.
28. Ben-Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, Porter AT, Tang DG: Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor. J Urol 1999; 161: 970-976.
29. Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, Spera G, Gnessi L: Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006; 175: 2072-2077.
30. Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N: Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010; 363: 1621-1630.